A phase I study of ALX148, a CD47 blocker, in combination with established anticancer antibodies in patients with advanced malignancy.

被引：10

作者：

Chow, Laura Quan Man

Gainor, Justin F.

Lakhani, Nehal J.

Chung, Hyun Cheol

Lee, Keun-Wook

Lee, Jeeyun

LoRusso, Patricia

Bang, Yung-Jue

Hodi, F. Stephen

Fanning, Philip

Zhao, Yonggang

Jin, Feng

Wan, Hong

Pons, Jaume

Randolph, Sophia

Messersmith, Wells A.

机构：

[1] Univ Washington, Div Med Oncol, Seattle, WA 98195 USA

[2] Massachusetts Gen Hosp, Boston, MA 02114 USA

[3] START Midwest, Grand Rapids, MI USA

[4] Yonsei Univ, Coll Med, Yonsei Canc Ctr, Seoul, South Korea

[5] Seoul Natl Univ, Bundang Hosp, Coll Med, Seongnam, South Korea

[6] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Seoul, South Korea

[7] Yale Univ, Sch Med, Yale Canc Ctr, New Haven, CT USA

[8] Seoul Natl Univ, Coll Med, Seoul, South Korea

[9] Dana Farber Canc Inst, Boston, MA 02115 USA

[10] ALX Oncol Inc, Burlingame, CA USA

[11] Univ Colorado, Comprehens Canc Ctr, Aurora, CO USA

来源：

关键词：

D O I：

10.1200/JCO.2019.37.15_suppl.2514

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

2514

引用

页数：2